pirenzepine has been researched along with Cognition Disorders in 34 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 9.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 9.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 6.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 5.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "The effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial." | 5.10 | Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. ( Green, MF; Harvey, PD; McGurk, SR; Meltzer, HY, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 5.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "P50 suppression of 13 patients with schizophrenia receiving clinically effective doses of clozapine, olanzapine, or risperidone (classified as atypical antipsychotic medications) was compared to that of 13 patients receiving conventional antipsychotic medications." | 3.70 | Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. ( Braff, DL; Cadenhead, KS; Clementz, BA; Geyer, MA; Light, GA, 2000) |
| " Subjective impairment, as assessed with the subscale 'mental functioning', was significantly correlated with greater conventional neuroleptic dosage after controlling for psychopathology (P<0." | 2.70 | Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. ( Krausz, M; Moritz, S; Naber, D; Woodward, TS, 2002) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 2.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "Risperidone has relatively consistent positive effects on working memory, executive functioning, and attention, whereas improvement in verbal learning and memory was inconsistent." | 2.40 | The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. ( McGurk, SR; Meltzer, HY, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 9 (26.47) | 18.2507 |
| 2000's | 23 (67.65) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nieves-Martinez, E | 1 |
| Haynes, K | 1 |
| Childers, SR | 1 |
| Sonntag, WE | 1 |
| Nicolle, MM | 1 |
| Lykouras, L | 1 |
| Typaldou, M | 1 |
| Gournellis, R | 1 |
| Vaslamatzis, G | 1 |
| Christodoulou, GN | 1 |
| Ondo, WG | 1 |
| Levy, JK | 1 |
| Vuong, KD | 1 |
| Hunter, C | 1 |
| Jankovic, J | 1 |
| Buchanan, RW | 1 |
| Summerfelt, A | 1 |
| Tek, C | 1 |
| Gold, J | 1 |
| Broerse, A | 1 |
| Crawford, TJ | 1 |
| den Boer, JA | 1 |
| de Haan, L | 1 |
| van Amelsvoort, T | 1 |
| Ichikawa, J | 1 |
| Chung, YC | 1 |
| Li, Z | 1 |
| Dai, J | 1 |
| Meltzer, HY | 3 |
| Aguglia, E | 1 |
| De Vanna, M | 1 |
| Onor, ML | 1 |
| Ferrara, D | 1 |
| Harvey, PD | 2 |
| Green, MF | 1 |
| McGurk, SR | 2 |
| Bokszanska, A | 1 |
| Martin, G | 1 |
| Vanstraelen, M | 1 |
| Holt, G | 1 |
| Bouras, N | 1 |
| Taylor, D | 1 |
| Napolitano, JA | 1 |
| Mao, L | 1 |
| Gharabawi, G | 1 |
| Brunnauer, A | 1 |
| Geiger, E | 1 |
| Laux, G | 1 |
| Wilson, MS | 1 |
| Gibson, CJ | 1 |
| Hamm, RJ | 1 |
| Dean, B | 1 |
| Teaktong, T | 1 |
| Piggott, MA | 1 |
| Mckeith, IG | 2 |
| Perry, RH | 2 |
| Ballard, CG | 1 |
| Perry, EK | 2 |
| Tsang, SW | 1 |
| Lai, MK | 1 |
| Kirvell, S | 1 |
| Francis, PT | 1 |
| Esiri, MM | 1 |
| Hope, T | 1 |
| Chen, CP | 1 |
| Wong, PT | 1 |
| Doods, HN | 1 |
| Quirion, R | 1 |
| Mihm, G | 1 |
| Engel, W | 1 |
| Rudolf, K | 1 |
| Entzeroth, M | 1 |
| Schiavi, GB | 1 |
| Ladinsky, H | 1 |
| Bechtel, WD | 1 |
| Ensinger, HA | 1 |
| Tollefson, GD | 3 |
| Keks, NA | 1 |
| Purdon, SE | 2 |
| Breier, A | 2 |
| Walker, Z | 1 |
| Grace, J | 1 |
| Overshot, R | 1 |
| Satarasinghe, S | 1 |
| Swan, A | 1 |
| Katona, CL | 1 |
| Andersen, SW | 1 |
| Tran, PV | 1 |
| Jones, BD | 1 |
| Stip, E | 1 |
| Labelle, A | 1 |
| Addington, D | 1 |
| David, SR | 1 |
| Light, GA | 1 |
| Geyer, MA | 1 |
| Clementz, BA | 1 |
| Cadenhead, KS | 1 |
| Braff, DL | 1 |
| Bhana, N | 1 |
| Foster, RH | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Risch, SC | 1 |
| McGurk, S | 1 |
| Horner, MD | 1 |
| Nahas, Z | 1 |
| Owens, SD | 1 |
| Molloy, M | 1 |
| Gilliard, C | 1 |
| Christie, S | 1 |
| Markowitz, JS | 1 |
| DeVane, CL | 1 |
| Mintzer, J | 1 |
| George, MS | 1 |
| Stephan, KE | 1 |
| Magnotta, VA | 1 |
| White, T | 1 |
| Arndt, S | 1 |
| Flaum, M | 1 |
| O'Leary, DS | 1 |
| Andreasen, NC | 1 |
| Moritz, S | 1 |
| Woodward, TS | 1 |
| Krausz, M | 1 |
| Naber, D | 1 |
| Kuroki, T | 1 |
| Tashiro, N | 1 |
| Sharma, T | 1 |
| Smith, CJ | 1 |
| Candy, JM | 1 |
| Johnson, M | 1 |
| Bonham, JR | 1 |
| Dick, DJ | 1 |
| Fairbairn, A | 1 |
| Blessed, G | 1 |
| Birdsall, NJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for pirenzepine and Cognition Disorders
| Article | Year |
|---|---|
Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology.
Topics: Animals; Benzodiazepinones; Brain; CHO Cells; Cognition Disorders; Cricetinae; Dibenzazepines; Drug | 1993 |
Cognitive function in schizophrenic patients.
Topics: Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Clozapine; Cognition Disorders; Dopamine; Gl | 1996 |
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cost-Benefit Analysis; Dibenz | 1998 |
[Use of novel agents in the treatment of schizophrenia and a look to the future].
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cognition Disorders; Hum | 1998 |
Cognitive improvement in schizophrenia with novel antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzothiazepines; Humans; O | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; H | 1999 |
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
Topics: Antipsychotic Agents; Attention; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cognition Dis | 1999 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
[Clinical and pharmacological studies of the second generation antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cytoskeletal Proteins; Dibenz | 2001 |
11 trials available for pirenzepine and Cognition Disorders
| Article | Year |
|---|---|
Olanzapine treatment for dopaminergic-induced hallucinations.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dopamine Agonists; Double-Blind Me | 2002 |
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Donepezil; Drug Therapy, Combinat | 2003 |
Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; | 2002 |
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Topics: Adolescent; Adult; Arousal; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2003 |
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Comorbidity; Di | 2003 |
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Human | 2003 |
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cluster Analysis; Cognition Disorders; Depressive Diso | 1999 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Me | 2000 |
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.
Topics: Adult; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Cognition Disorders; Cross-Over Studies | 2001 |
Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebellum; Cognition Disorders; Female; Humans; Magne | 2001 |
Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dose-Response Relation | 2002 |
14 other studies available for pirenzepine and Cognition Disorders
| Article | Year |
|---|---|
Muscarinic receptor/G-protein coupling is reduced in the dorsomedial striatum of cognitively impaired aged rats.
Topics: Aging; Animals; Attention; Autoradiography; Cognition Disorders; Corpus Striatum; Food Deprivation; | 2012 |
Coexistence of Capgras and Frégoli syndromes in a single patient. Clinical, neuroimaging and neuropsychological findings.
Topics: Adult; Benzodiazepines; Brain; Capgras Syndrome; Cognition Disorders; Depersonalization; Female; Hum | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenze | 2002 |
Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Topics: Acetylcholine; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Cognition Disorders; Dopamine; Ma | 2002 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Hal | 2002 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combinat | 2003 |
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Cognition Diso | 2003 |
M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia.
Topics: Brain Chemistry; Cognition Disorders; Humans; Muscarinic Agonists; Muscarinic Antagonists; Pirenzepi | 2004 |
Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Autoradiography; Binding, Competitive; Case-Control S | 2005 |
Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brain Chemistry; Choline O-Acetylt | 2006 |
Olanzapine in dementia with Lewy bodies: a clinical study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Contraindicatio | 1999 |
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Clozapine; | 2000 |
Atypical antipsychotics and cognition in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dose-Response Relationship, D | 2002 |
Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders.
Topics: Acetylcholinesterase; Aging; Choline O-Acetyltransferase; Cognition Disorders; Hippocampus; Humans; | 1988 |